Molecular Study of Individual Radiosensitivity in Children and Teens with Cancer Using Blood Tests to Understand Radiation Effects

What this Trial Is About

This research aims to analyze individual radiosensitivity in children and adolescents with cancer, focusing on how their bodies respond to radiation therapy. It targets pediatric patients treated for brain tumors, Ewing tumors, malignant mesenchymal tumors, neuroblastoma, nephroblastoma, or Hodgkins lymphoma who are undergoing radiotherapy, sometimes alongside chemotherapy, for curative purposes. The study is sponsored by Neolys and investigates a blood test called RadioDtect to predict radiation-related toxicities. Participants will provide blood samples to perform the RadioDtect test, which involves collecting two 5 ml blood samples. The study evaluates the tests ability to identify early and late radiation-induced toxicities over periods of 12 and 24 months. The radiation treatments follow standard fractionation schedules, typically 1.8 Gy to 2.2 Gy per fraction, five fractions per week. During the study, participants will undergo blood sample collection and be monitored for any side effects related to radiation therapy. Researchers will assess early and late radiation-induced toxicities to validate the tests predictive capacity. The study includes follow-up assessments up to 24 months to track outcomes, with participation lasting through these evaluation periods.

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology